Portola Pharmaceuticals Inc operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Portola Pharmaceuticals Inc with three other
companies in this sector in the United States:
Caladrius Biosciences Inc
sales of $35.28 million
of which 100%
was PCT Segment),
Jounce Therapeutics Inc
Aratana Therapeutics Inc
Sales increased substantially in 2016:
During the year ended December of 2016, sales at
Portola Pharmaceuticals Inc were $35.50 million.
increase of 194.2%
versus 2015, when the company's sales were $12.07 million.